Cardiff Oncology, Inc. - 8-K Filing
Cardiff Oncology filed an 8-K to disclose a Phase 2 CRDF-004 clinical trial update for onvansertib in first-line RAS-mutated metastatic colorectal cancer (mCRC). The interim results showed a 72% objective response rate (ORR) with the combination of onvansertib and standard-of-care chemotherapy/bevacizumab, compared to 42.1% for control arms. A Phase 3 trial is planned using this regimen. (Items: 7.01 Regulation FD Disclosure, 9.01 Financial Statements and Exhibits)
Tickers: $CRDF